Enalapril in therapy of arterial hypertension in patients with juvenile obesity
https://doi.org/10.14341/probl12187
Abstract
Clinical efficacy of enalapril, a drug belonging to a group of angiotensin-converting enzyme inhibitors, was studied in patients with pubertal juvenile dyspituitarism (juvenile obesity) coursing with arterial hypertension. A reactive increase of plasma renin activity and reduced concentration of plasma aldosterone were revealed. The drug was characterized by a pronounced hypotensive effect. No negative effects on the blood lipid spectrum or carbohydrate metabolism were observed. The study showed that enalapril may be a drug of choice in the treatment of the hypertensive syndrome in patients with juvenile obesity.
About the Authors
Ye. V. MalyghinaRussian Federation
G. A. Gherasimov
Russian Federation
T. M. Atamanova
Russian Federation
References
1. Кукес В.Г., Насыров Ш.Н., Волчонок В.И. и др. // Кардиология. - 1990. - № 3. - С. 28-32.
2. Метелица В.И. // Справочник кардиолога по клинической фармакологии. — М., 1987. — С. 161—201.
3. Campbell D.J. // J. clin. Invest. — 1987. — Vol. 79. — P. 1—6.
4. Dzau V.J. // Hypertension. — 1986. — Vol. 8. — P. 553—565.
5. Free A., Miiller-Brand J. // Ibid. — 1986. — Vol. 4. — P. 365— 367.
6. Gomez H.J, Cirillo V.J., Irvin J.D. // Drugs. — 1985. — Vol. 30, Suppl. 1. — P. 13—24.
7. Guidon J. // J. int. Med. - 1988. - Vol. 88, N 117. - P. 912.
8. Laragh J.H., Cose D.B., Allas S.A. et al. // Hypertension. — 1980. - Vol. 2. — P. 586-593.
9. Lombardi C.M., Missale C., Poli M., de Cotiis R. // Minerva med. - 1990. - Vol. 81, N 9. - P. 587-590.
10. Smales J.D. // J. cardiovasc. Pharmacol. — 1987. — Vol. 9, Suppl. 13. - P. S22-S25.
11. Webb D.S., Collier J.G. // Ibid. - 1986. - Vol. 8, Suppl. 10. - P. S40 S44.
Review
For citations:
Malyghina Ye.V., Gherasimov G.A., Atamanova T.M. Enalapril in therapy of arterial hypertension in patients with juvenile obesity. Problems of Endocrinology. 1994;40(6):25-26. (In Russ.) https://doi.org/10.14341/probl12187

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).